Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Breast cancer, early stage

2397 - Primary results of LORELEI: a phase II randomized, double-blind study of neoadjuvant letrozole (LET) plus taselisib versus LET plus placebo (PLA) in postmenopausal patients (pts) with ER+/HER2-negative early breast cancer (EBC)

Date

08 Sep 2017

Session

Breast cancer, early stage

Topics

Cytotoxic Therapy;  Breast Cancer;  Prostate Cancer

Presenters

Cristina Saura

Citation

Annals of Oncology (2017) 28 (suppl_5): v605-v649. 10.1093/annonc/mdx440

Authors

C. Saura1, E. de Azambuja2, D. Hlauschek3, M. Oliveira4, D. Zardavas5, A. Jallitsch-Halper3, L. de la Pena6, P. Nuciforo7, A. Ballestrero8, M.N. Fornier9, K. Boer10, E. Ciruelos11, V. Valero12, T.R. Wilson13, T.J. Stout13, J.Y. Hsu13, Y. Shi13, M. Piccart2, M. Gnant14, J. Baselga15

Author affiliations

  • 1 Medical Oncology Department, Vall d’Hebron University Hospital, Vall d’Hebron Institute of Oncology, 08035 - Barcelona/ES
  • 2 Medical Oncology, Institute Jules Bordet, 1000 - Brussels/BE
  • 3 Abcsg, Austrian Breast & Colorectal Cancer Study Group, 1190 - Vienna/AT
  • 4 Medical Oncology Department, Vall d’Hebron University Hospital, Vall d’Hebron Institute of Oncology, Barcelona/ES
  • 5 Brussels, Breast International Group, 1000 - Brussels/BE
  • 6 Solti, SOLTI BREAST CANCER RESEARCH, Barcelona/ES
  • 7 Molecular Oncology Group, Vall d´Hebron Institute of Oncology, 08035 - Barcelona/ES
  • 8 & Goirc, University of Genoa-IRCCS AOU San Martino IST, Genova/IT
  • 9 Medical Oncology, Memorial Sloan-Kettering Cancer Center, 10065 - New York/US
  • 10 Medical Oncology, St. Margit Hospital, 1034 - Budapest/HU
  • 11 Medical Oncology, University Hospital 12 De Octubre, 28041 - Madrid/ES
  • 12 Medical Oncology, MD Anderson Cancer Center, 77030-4095 - Houston/US
  • 13 --, Genentech Inc. - Roche - USA, 94080 - South San Francisco/US
  • 14 Department Of Surgery And Comprehensive Cancer Center  , Medical University of Vienna, 1090 - Vienna/AT
  • 15 --, Memorial Sloan-Kettering Cancer Center, 10065 - New York/US
More

Resources

Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

Abstract 2397

Background

Taselisib is an oral, potent, and selective PI3-kinase (PI3K) inhibitor with enhanced activity against PIK3CA mutant (MUT) cancer cells. Confirmed partial responses were observed in pts with PIK3CA MUT metastatic breast cancer treated with taselisib as a single agent and combined with endocrine therapy (ET).

Methods

334 postmenopausal pts with ER+/HER2-, Stage I-III, operable EBC and evaluable tumor tissue for centralized PIK3CA genotyping were randomized (1:1) in 90 sites worldwide to receive LET with either taselisib (4mg 5 days on/2 days off) or PLA for 16 weeks, followed by surgery. Co-primary endpoints: objective response rate (ORR) by centrally assessed breast MRI and pathologic complete response (pCR, ypT0/is N0) rate at surgery, in all randomized pts and in pts with PIK3CA MUT tumors. The sample size was calculated to detect in the PIK3CA MUT subset an absolute increase of 24% in ORR (from 40% to 64%, minimal detectable difference [MDD] 15%; 2-sided α 16%, 80% power), and 18% in pCR (from 1% to 19%; MDD 13%; 2-sided α 4%, 80% power).

Results

The study met its primary endpoint: the addition of taselisib to LET increased the ORR from 38% to 56.2% in the PIK3CA MUT subset (N = 152; Odds ratio [OR] 2.03, 95%CI 1.06-3.88, p = 0.033) and in all randomized pts (from 39.3% to 50%, OR 1.55, 95%CI 1.00-2.38, p = 0.049). No significant difference was observed for pCR rate overall or in the PIK3CA MUT subset. Most common G3-4 adverse events in the taselisib arm: gastrointestinal disorders (7.8%), infections (4.8%), and skin/subcutaneous tissue disorders (4.8%). G3-4 hyperglycemia occurred in 1.2% of pts. One sudden death occurred in the taselisib arm, but was considered unrelated to study treatment. Taselisib discontinuation (10.8%) and dose reductions (11.4%) were infrequent.

Conclusions

LORELEI is the first randomized study to demonstrate a significant increase in ORR measured by MRI upon treatment with a PI3K selective inhibitor + ET in ER+/HER2- EBC pts. Toxicity was manageable. Ongoing comprehensive biomarker analyses will provide further insight into the antitumor responses observed with this combination.

Clinical trial identification

NCT02273973

Legal entity responsible for the study

Colead partnership between Genentech (Sponsor) - BIG (Governance & coordination) - ABCSG (data center) - SOLTI (biosamples)

Funding

Genentech Inc.

Disclosure

T.R. Wilson, Y. Shi: Employed by Genentech Inc., stocks in Roche. T.J. Stout: Employed by Genentech Inc. J.Y. Hsu: Employed by Genentech Inc., M. Piccart: Consultant (honoraria) from Roche-Genentech, Research grants to my Institute from Roche-Genentech. M. Gnant: Honoraria: Roche Research Funding: Roche. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.